Cadence, Incline Therapeutics deal

Cadence declined to exercise an option to acquire Incline for up to $135 million during the first of two option periods. The company said it made the decision because it wants to focus on the launch of pain and fever drug Ofirmev IV acetaminophen. Cadence can still acquire the neurology company for up to $228 million during a second option period, which extends until the earliest to occur of: 30 days after Incline submits an sNDA to FDA for its Ionsys fentanyl transdermal system to treat post-operative pain; 30 days after Incline files for an IPO; or December 2013 (see BioCentury, June 28, 2010). ...